How do you improve patient recruitment and diversity in clinical trials?

Engaging community physicians (provider-engagement models like MedVector's) widens access to larger, more diverse patient populations, while Latin America's large, treatment-naïve populations help sponsors meet FDA Diversity Action Plan expectations — and recruit faster.

From the Global Trial Accelerators™ podcast with Scott Stout (MedVector): watch the episode.

What drives faster, more diverse recruitment

Provider-engagement models reach patients through trusted community physicians
Large, treatment-naïve Latin American populations enroll quickly
Diversity that supports FDA Diversity Action Plan (DAP) requirements
Centralized sites with high patient volumes shorten enrollment timelines
Faster recruitment lowers the per-patient carrying cost of a long enrollment window

Frequently asked questions

Why is patient diversity important to the FDA?

The FDA increasingly expects trial populations to reflect the diversity of the intended-use population under its Diversity Action Plan guidance. Diverse enrollment improves the generalizability and safety evidence of a device or drug. Latin America's large, varied populations can strengthen a sponsor's diversity profile.

How does Latin America speed up recruitment?

Latin American sites often have large, centralized, treatment-naïve patient populations and high per-site volumes, which shortens the time to enroll a first-in-human or early-feasibility cohort compared with fragmented US recruitment.

What is a provider-engagement recruitment model?

It's an approach that engages community healthcare providers to offer trials as a care option to their patients — without requiring those physicians to become investigators — unlocking access to larger, more diverse patient pools than traditional site-based recruitment.